A biopharmaceutical company developing first-in-class therapies for solid tumor cancers and autoimmune diseases.
Thetis’ drug candidates are based on a novel class of pro-resolving mediators (“Resolvins”) discovered by biomedical scientists at Harvard Medical School. Their pioneering research has shown that Resolvins are potent agonists of inflammation resolution and tissue repair that can be delivered therapeutically to counteract an overactive inflammatory response without compromising immune function.
Thetis’ HEALER™ technology platform enables the development of Resolvins as new molecular entities with enhanced stability and bioavailability, overcoming key hurdles that have historically limited their development as pharmaceutical drugs. Thetis is leveraging this technology to develop a pipeline of drug candidates for cancers and autoimmune diseases.
Our lead candidate is a novel Resolvin E1 small molecule therapy (TP-317) being developed in solid tumor cancers and inflammatory bowel disease (IBD). TP-317 offers a differentiated therapeutic strategy that harnesses natural resolution mechanisms without suppressing the immune system. Based on Phase 1 clinical trials demonstrating the favorable safety and tolerability of orally administered RvE1 in healthy volunteers, Thetis plans to advance TP-317 rapidly into clinical development in 2022.
Beyond TP-317, Thetis’ technology platform enables the development additional Resolvin in various diseases. In addition, Thetis has a collaboration with NIH to leverage the HEALER platform in inflammatory liver diseases.